Wai H Lim1, Jeremy R Chapman, Germaine Wong. 1. 1 Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. 2 Centre for Transplant and Renal Research, Westmead Hospital, New South Wales, Australia. 3 Sydney School of Public Health, University of Sydney, New South Wales, Australia. 4 Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.
Abstract
BACKGROUND: High levels of pretransplant panel reactive antibodies (PRA) are known to be associated with detrimental effects on graft outcomes, but the association between pretransplant PRA levels and long-term patient outcomes is unclear. METHODS: Using the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), we assessed the risk of rejection, graft failure, mortality and cancer in kidney transplant recipients with varying peak PRA levels. RESULTS: In 7,118 kidney transplant recipients between 1997 and 2009, there were a total of 3,171 (44.6%), 3,306 (46.4%), 323 (4.5%), and 318 (4.5%) recipients with peak PRA levels of 0%, 1% to 50%, 51% to 80%, and greater than 80%, respectively. Compared to recipients with 0% peak PRA level, recipients with peak PRA levels greater than 80% were at increased risk of acute rejection (odds ratio, 1.81, 95% confidence interval [95% CI], 1.30-2.35; P < 0.001), death censored graft failure (hazard ratio [HR], 2.06; 95% CI, 1.46-2.91; P < 0.001), all-cause mortality (HR, 1.56; 95% CI, 1.15-2.11; P < 0.001) and cancer (HR, 1.94; 95% CI, 1.26-2.97; P = 0.002) in the adjusted models independent of human leukocyte antigen mismatches and initial immunosuppression. CONCLUSION: Highly sensitized kidney transplant recipients with peak PRA greater than 80% had a greater risk of rejection, graft failure, cancer and death independent of age and time on dialysis. Strategies to reduce transplant waiting time and avoidance of sensitization in all potential transplant candidates are imperative to improve the overall graft and patient survival.
BACKGROUND: High levels of pretransplant panel reactive antibodies (PRA) are known to be associated with detrimental effects on graft outcomes, but the association between pretransplant PRA levels and long-term patient outcomes is unclear. METHODS: Using the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), we assessed the risk of rejection, graft failure, mortality and cancer in kidney transplant recipients with varying peak PRA levels. RESULTS: In 7,118 kidney transplant recipients between 1997 and 2009, there were a total of 3,171 (44.6%), 3,306 (46.4%), 323 (4.5%), and 318 (4.5%) recipients with peak PRA levels of 0%, 1% to 50%, 51% to 80%, and greater than 80%, respectively. Compared to recipients with 0% peak PRA level, recipients with peak PRA levels greater than 80% were at increased risk of acute rejection (odds ratio, 1.81, 95% confidence interval [95% CI], 1.30-2.35; P < 0.001), death censored graft failure (hazard ratio [HR], 2.06; 95% CI, 1.46-2.91; P < 0.001), all-cause mortality (HR, 1.56; 95% CI, 1.15-2.11; P < 0.001) and cancer (HR, 1.94; 95% CI, 1.26-2.97; P = 0.002) in the adjusted models independent of human leukocyte antigen mismatches and initial immunosuppression. CONCLUSION: Highly sensitized kidney transplant recipients with peak PRA greater than 80% had a greater risk of rejection, graft failure, cancer and death independent of age and time on dialysis. Strategies to reduce transplant waiting time and avoidance of sensitization in all potential transplant candidates are imperative to improve the overall graft and patient survival.
Authors: Abbas Rana; Bhamidipati Murthy; Zachery Pallister; Michael Kueht; Ronald Cotton; N Thao N Galvan; Whiston Etheridge; Hau Liu; John Goss; Christine O'Mahony Journal: J Nephrol Date: 2016-09-29 Impact factor: 3.902
Authors: Raquel Garcia-Roca; Ivo G Tzvetanov; Hoonbae Jeon; Elisabeth Hetterman; Jose Oberholzer; Enrico Benedetti Journal: World J Gastrointest Surg Date: 2016-01-27
Authors: James H Lan; Matthew Kadatz; Doris T Chang; Jagbir Gill; Howard M Gebel; John S Gill Journal: Clin J Am Soc Nephrol Date: 2021-01-25 Impact factor: 8.237
Authors: Sunjae Bae; Mara A McAdams-DeMarco; Allan B Massie; Jacqueline M Garonzik-Wang; Josef Coresh; Dorry L Segev Journal: Transplantation Date: 2022-03-01 Impact factor: 5.385
Authors: Zaid Brifkani; Daniel C Brennan; Krista L Lentine; Timothy A Horwedel; Andrew F Malone; Rowena Delos Santos; Thin Thin Maw; Tarek Alhamad Journal: Transplant Direct Date: 2017-02-08
Authors: Burç Dedeoglu; Ruud W J Meijers; Mariska Klepper; Dennis A Hesselink; Carla C Baan; Nicolle H R Litjens; Michiel G H Betjes Journal: PLoS One Date: 2016-03-07 Impact factor: 3.240
Authors: Rong Hu; Daniel T Barratt; Janet K Coller; Benedetta C Sallustio; Andrew A Somogyi Journal: Front Pharmacol Date: 2020-02-20 Impact factor: 5.810